Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of FWD1802 versus investigator's choice endocrine therapy in ESR1-mutant ER-positive/HER2-negative advanced or metastatic breast cancer
CTR20263652Phase 3Active
- Sponsor
- Forward Pharma
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fwd1802 in breast cancer (2 arms), sponsored by Forward Pharma. Primary endpoint: Progression-free survival by BICR per RECIST v1.1. Started Oct 2026; status: active.
02
Drugs
fwd1802
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263652.